Quintrio
Home

Stock overview

Clearmind Medicine Inc. Common Shares

CMND

Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $3.39 – $4.10
Volume 11,567
Market cap $2M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for CMND.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for CMND.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial

Clearmind Medicine announced successful completion of treatment for all 24 participants in Part A of its Phase I/II clinical trial evaluating CMND-100 for alcohol use disorder. The multicenter trial, conducted under FDA oversight at leading U.S. and Israeli research institutions, is progressing to data review with plans to advance to the next phase of development pending favorable results.

GlobeNewswire Inc.

Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market

Clearmind Medicine Inc. (Nasdaq: CMND) filed a patent application with the Hong Kong Patent Office for innovative psychedelic compounds targeting PTSD treatment. The filing is part of an exclusive licensing agreement with Yissum Research Development Company of Hebrew University. The global PTSD treatment market is valued at USD 18.5 billion in 2025 and projected to reach USD 30.2 billion by 2035, with Clearmind positioning Hong Kong as a strategic gateway for Asian market access.

GlobeNewswire Inc.

Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight

The substance use disorder market is expected to grow between 2025 and 2034, driven by greater awareness, the introduction of new therapies, and ongoing research and development efforts. The report covers the market assessment of Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder.

GlobeNewswire Inc.

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

SciSparc and Clearmind Medicine have filed an international patent application for a novel treatment targeting anorexia, bulimia, and other eating disorders. The treatment combines 3-Methylmethcathinone (3-MMC) with SciSparc's Palmitoylethanolamide (PEA) to address the complex neurobiological and psychological factors associated with eating disorders.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 5, 20261-for-8reverse split
May 21, 20261-for-10reverse split
Dec 15, 20251-for-40reverse split
Nov 28, 20231-for-30reverse split
Jul 3, 20173.5-for-1forward split